U.K. Industry Promotes Real World Data As Backbone Of Value-Based Purchasing, Despite Government Lethargy
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K. government has sidelined the VBP debate, preferring to focus on other aspects of health care reform, but industry is pressing ahead with its vision for pricing and reimbursement evaluation.
You may also be interested in...
NICE Again Rejects Xarelto, This Time In DVT Indications
U.K. cost watchdog NICE asks for further data on use of Bayer's Xarelto for the treatment and prevention of deep vein thrombosis, having made similar demands at the start of the year on its use in atrial fibrillation.
U.K. To Leverage NHS Data As Part Of Broader Stimulus Package, But Details Still Sketchy
Industry welcomed the initiatives, which included making National Health Service clinical data more widely available and strengthening NICE's role.
NICE Will Have Key Role in Value-Based Pricing Under U.K. Health Care Reforms
NICE to be placed on a firmer statutory footing and given a new name, as well as a role in determining the value of medicines.